GlassScriptPhysician profile
Gregory R Crisp
NPI 1649708744
$9,414.91
in general payments reported to CMS, 2019-2025
25 companies · $969 in 2025
The $969 reported for 2025 was more than what a typical Pain Medicine (Anesthesiology) provider received nationally (typical 2025 total: $458).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $451 · 2020: $78.38 · 2021: $725 · 2022: $3,897 · 2023: $1,813 · 2024: $1,482 · 2025: $969.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,142 · Travel and Lodging: $122.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,141.90 |
| Travel and Lodging | $122.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,829.74 | 2022-2025 | Intracept Rf Probe, General - Pain Management, Intracept |
| Medtronic, INC. | $1,731.45 | 2021-2025 | Kyphon Express II Kyphopak Tray, Intellis Adaptivestim |
| Nevro Corp. | $1,620.15 | 2021-2024 | Senza |
| Vertos Medical, INC. | $843.96 | 2021-2024 | Mild Device Kit |
| Relievant Medsystems, INC. | $587.13 | 2022-2023 | Intracept |
| Abbvie INC. | $575.64 | 2023-2025 | Qulipta, Botox |
| Abbott Laboratories | $344.40 | 2019-2021 | |
| Collegium Pharmaceutical, INC. | $320.15 | 2023-2024 | Belbuca, Xtampza |
| Si-Bone, INC. | $227.87 | 2021-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $224.57 | 2022-2025 | Relistor |
| Globus Medical, INC. | $218.77 | 2025 | Senza |
| Pfizer INC. | $168.20 | 2023-2025 | |
| Vertiflex, INC. | $149.04 | 2019 | |
| Avanos Medical | $142.70 | 2022 | |
| Nalu Medical, INC. | $116.48 | 2023 | Nalu Neurostimulation System |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $104.24 | 2019 | |
| Janssen Biotech, INC. | $65.77 | 2020 | |
| Masimo Corporation | $24.27 | 2019 | |
| Radius Health, INC. | $20.37 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $19.41 | 2022 | |
| Stryker Corporation | $17.98 | 2023 | Spinejack |
| Bioventus LLC | $17.88 | 2023 | Durolane |
| Convatec INC. | $17.47 | 2025 | |
| Lilly USA, LLC | $15.20 | 2023 | Emgality |
| Biohaven Pharmaceutical Holding Company LTD. | $12.07 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Crisp listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.